STROBE Statement—checklist of items that should be included in reports of observational studies

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Item No. | Recommendation | Page No. | Relevant text from manuscript |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract | 1 | Clinimetric properties |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | 1-2 | See abstract. |
| Introduction |  |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3-4 | See introduction, lines 99-127 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4 | Therefore, the aims of this study were to (1) validate the WBB against a laboratory-grade force plate to measure COP and subsequently (2) to provide an open-source web application to reduce analysis time, need for technical skills, ease of use and thereby improve clinical implementation of posturography. |
| Methods |  |
| Study design | 4 | Present key elements of study design early in the paper | 4 | cross-sectional study |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 | See materials & methods, lines 130-137 |
| Participants | 6 | (*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up*Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls*Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants | 4 | See materials & methods, lines 130-140 |
| (*b*)*Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed*Case-control study*—For matched studies, give matching criteria and the number of controls per case | N/A | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5 | See materials & methods, lines 188-193 |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5 | See materials & methods, lines 155-170 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 5 | See materials & methods, lines 178-188  |
| Study size | 10 | Explain how the study size was arrived at | 4 | See materials & methods, lines 132-133 |

Continued on next page

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 5 | See materials & methods, lines 171-188 and figure 1 and 2. |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | 5 | See materials & methods, lines 171-188 and 194-209 |
| (*b*) Describe any methods used to examine subgroups and interactions | N/A | N/A |
| (*c*) Explain how missing data were addressed | 6 | See results, lines 218 - 221 |
| (*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed*Case-control study*—If applicable, explain how matching of cases and controls was addressed*Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy | N/A | N/A |
| (*e*) Describe any sensitivity analyses | N/A | N/A |
| Results |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 6 | See results, lines 214-222 |
| (b) Give reasons for non-participation at each stage | 6 | See results, lines 214-222 |
| (c) Consider use of a flow diagram | N/A | N/A |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 6 | See results, lines 214-218 and table 1. |
| (b) Indicate number of participants with missing data for each variable of interest | 6 | See results, lines 218-221 |
| (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) | N/A | N/A |
| Outcome data | 15\* | *Cohort study*—Report numbers of outcome events or summary measures over time | N/A | N/A |
| *Case-control study—*Report numbers in each exposure category, or summary measures of exposure | N/A | N/A |
| *Cross-sectional study—*Report numbers of outcome events or summary measures | 6-8 | See results, lines 214 and table 2-5. |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | N/A | N/A |
| (*b*) Report category boundaries when continuous variables were categorized | N/A | N/A |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A | N/A |

Continued on next page

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 8 | See results, lines 280-295 and figure 3 to 7 |
| Discussion |
| Key results | 18 | Summarise key results with reference to study objectives | 8-9 | See discussion, lines 298-321. |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 9-10 | See discussion, lines 337-376 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 8-9 | See discussion, lines 298-326 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 11 | See discussion, lines 414-424 |
| Other information |  |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | - | Provided through online PeerJ manuscript submission system. |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.